Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, Virus-based gene therapy research, and Viral Infectious Diseases and Gene Expression in Insects.
Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.
Vitamin C Conditioning Generates Tumor-Targeting CAR T Cells with Superior Cytotoxicity and Fitness in a Posttransplant Lymphoproliferative Disorder Tumor Model.
Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination.
Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.
Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.
ROR1 CAR T cells and lenvatinib cooperatively target anaplastic thyroid carcinoma
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies
Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma.
Autocrine signaling in hormonally active cancer induces antigen expression for immunotherapy
Boosting immune cells to combat cancer using CRISPR engineering and large-scale in vivo testing.
<scp>LMP2A</scp> ‐Targeting <scp>CAR</scp> ‐T Cells Equipped With Inducible <scp>IL</scp> ‐18 to Address <scp>EBV</scp> ‐Associated Malignancies
Fine tuning towards the next generation of engineered T cells.
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.
TCR activation impairs CAR-T cytotoxicity against separate target cells
A novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors
Trust in and Acceptance of Artificial Intelligence Applications in Medicine: Mixed Methods Study.
CAR T-cell therapy in multiple myeloma: mission accomplished?
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
BCMA CAR-T cells in multiple myeloma-ready for take-off?
Mutation-specific CAR T cells as precision therapy for IGLV3-21<sup>R110</sup> expressing high-risk chronic lymphocytic leukemia.
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells.
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity.
TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation.
Cellular Therapies for Multiple Myeloma: Engineering Hope.
Teclistamab impairs detection of BCMA CAR-T cells.
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.